Search | Page 4 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Azacitidine-lenalidomide (ViLen) combination yields a high response rate in higher risk myelodysplastic syndromes (MDS)-ViLen-01 protocol

    ... hematologic- thrombocytopenia (20 patients) and neutropenia (13 patients). The common non-hematologic AEs were infections ...

    Research Article last updated 09/13/2016 - 2:47pm.

  2. Bone marrow hypocellularity does not affect tolerance or efficacy of azacitidine in patients with higher-risk myelodysplastic syndromes

    ... of cellularity. Grade 3-4 thrombocytopenia and neutropenia occurred similarly in hypocellular patients treated with ...

    Research Article last updated 02/04/2014 - 1:32pm.

  3. Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy.

    ... tolerated. Grade III-IV thrombocytopenia and neutropenia occurred after 9.5 and 30% of the cycles, respectively, while ...

    Research Article last updated 10/11/2011 - 5:58pm.

  4. Professionals

    Resources Health care providers are the primary source of information for their patients, but they too need access to factual and...

    Page last updated 05/03/2018 - 2:28pm.

  5. What are the symptoms of low blood counts?

    ... Count A low white blood cell count is called neutropenia . If you have a low white blood cell count, you may: ...

    FAQ last updated 04/28/2016 - 4:49pm.

  6. Antibiotics

    ... don't have enough healthy neutrophils are said to have neutropenia . Because of their low white count, they may get infections ... and have trouble getting rid of infections. If you have neutropenia, your doctor may ask you to take antibiotics. These medicines help ...

    Page last updated 11/13/2014 - 10:00am.

  7. Marrow protein may be key to SCT success

    ... undergoing chemotherapy who develop febrile neutropenia , associated with low levels of white blood cells, might benefit ...

    Article last updated 08/29/2017 - 11:18am.

  8. Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents

    ... The most common treatment-emergent adverse events were neutropenia and thrombocytopenia . CONCLUSION: Lenalidomide ...

    Research Article last updated 07/18/2016 - 10:30am.

  9. Myelodysplastic syndromes: Contemporary review and how we treat

    ... (ESAs, danazol, HMA), thrombocytopenia (HMA), or neutropenia (myeloid growth factors). Conversely, there is no controlled ...

    Research Article last updated 04/29/2016 - 1:05pm.

  10. Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial

    ... group), thrombocytopenia (35 [19%] vs six [7%]), neutropenia (31 [17%] vs seven [8%]), febrile neutropenia (22 [12%] vs ten [11%]), and pneumonia (22 [12%] vs ten [11%]). 41 ...

    Research Article last updated 06/07/2016 - 11:10am.